

ITW

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature and Deposit: May 7, 2004


Zhibin Ren 47,897

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mark E. Cook, et al.

Date: May 7, 2004

Serial No.: 10/756,719

Group Art Unit: --

Filed: 01/13/2004

Examiner: --

Title: METHOD OF TREATING TYPE III
HYPERSENSITIVE REACTION-RELATED
DISEASES AND CONDITIONS BY USING
CONJUGATED LINOLEIC ACID

File: 960296.00108

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is a completed Information Disclosure Statement by Applicants listing documents that the applicants in the above-identified application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application.

No fee is believed due in connection with this submission. However, if a fee is due, please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,



Zhibin Ren
Reg. No. 47,897
Attorney for Applicants
QUARLES & BRADY LLP
411 East Wisconsin Ave.
Milwaukee, WI 53202
TEL 414-277-5633
FAX 414-277-3552



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 0.00

Complete if Known

Application Number 10/756,719
Filing Date 01/13/2004
First Named Inventor Mark E. Cook
Examiner Name --
Art Unit --
Attorney Docket No. 960296.00108

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit
Account
Number
Deposit
Account
Name

17-0055

Quarles & Brady LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1)			(\$) 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20* =	X	0.00
Multiple Dependent	-3** =	X	0.00

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

*or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0.00

SUBMITTED BY

Name (Print/Type) Zhibin Ren Registration No. 47,897 Telephone 414-277-5633
Signature [Signature] (Attorney/Agent) Date May 7, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

5574710

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**Complete if Known**

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Application Number	10/756,719
Filing Date	01/13/2004
First Named Inventor	Mark E. Cook
Art Unit	--
Examiner Name	--
Attorney Docket Number	960296.00108

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

5574505

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/756,719		
		Filing Date	01/13/2004		
		First Named Inventor	Mark E. Cook		
		Art Unit	--		
		Examiner Name	--		
Sheet	2	of	3	Attorney Docket Number	960296.00108

OTHER PRIOR ART–NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6	LEAH D. WHIGHAM, ET AL., Decreased antigen-induced eicosanoid release in conjugated linoleic acid-fed guinea pigs; Am J Physiol Regulatory Integrative Comp Physiol 282: R1104-R1112, 2002.	
	7	LEAH D. WHIGHAM, ET AL., CLA reduces antigen-induced histamine and PGE2 release from sensitized guinea pig tracheae; Am J Physiol Regulatory Integrative Comp Physiol 280: R908-R912, 2001.	
	8	BOON P. CHEW, ET AL., Effects of Conjugated Dienoic Derivatives of Linoleic Acid and β-Carotene in Modulating Lymphocyte and Macrophage Function; Anticancer Research 17: 1099-1106 (1997).	
	9	LINDA K. MYERS, ET AL., Collagen-Induced Arthritis, an Animal Model of Autoimmunity; Life Sciences, Vol. 61, No. 19, pp. 1861-1878, 1997.	
	10	G. SRAVAN KUMAR, ET AL., Effect of n-6 and n-3 Fatty Acids on the Proliferation of Human Lymphocytes and their Secretion of TNF-α and IL-2 In Vitro; Nutrition Research, Vol. 12, pp. 815-823, 1992.	
	11	C.C. MILLER, ET AL., Feeding Conjugated Linoleic Acid to Animals Partially Overcomes Catabolic Responses Due to Endotoxin Injection; Biochemical and Biophysical Research Communications, Vol. 198, No. 3, pp. 1107-1112, 1994.	
	12	MICHIHIRO SUGANO, ET AL., Lymphatic recovery, tissue distribution, and metabolic effects of conjugated linoleic acid in rats; J Nutr. Biochem., Vol. 8, pp. 38-43, 1997.	
	13	MICHIHIRO SUGANO, ET AL., Conjugated Linoleic Acid Modulates Tissue Levels of Chemical Mediators and Immunoglobulins in Rats, Lipids; Vol. 33, No. 5, pp. 521-527, 1998.	
	14	KAI-LI LIU, ET AL., Conjugated linoleic acid reduces arachidonic acid content and PGE2 synthesis in murine keratinocytes; Cancer Letters 127: pp. 15-22, 1998.	
	15	MUN WAH WONG, ET AL., Effects of Dietary Conjugated Linoleic Acid on Lymphocyte Function and Growth of Mammary Tumors in Mice; AntiCancer Research, Vol. 17: pp. 987-994, 1997.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/756,719		
		Filing Date	01/13/2004		
		First Named Inventor	Mark E. Cook		
		Group Art Unit	--		
		Examiner Name	--		
Sheet	3	of	3	Attorney Docket Number	960296.00108

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	C. WEYMAN, ET AL., Linoleic Acid as an Immunosuppressive Agent; Lancet 2: pg. 33, 1975.	
	17	YEONHWA PARK, ET AL., Effect of Conjugated Linoleic Acid on Body Composition in Mice; Lipids, Vol. 32, No. 8, pp. 853-858, 1997.	
	18	M. E. COOK, ET AL., Immune Modulation by Altered Nutrient Metabolism: Nutritional Control of Immune-Induced Growth Depression; Poultry Science, 72, pp. 1301-1305, 1993.	
	19	MINGDER YANG, ET AL., Dietary Conjugated Linoleic Acid Protects Against End Stage Disease of Systemic Lupus Erythematosus in the NZB/W F1 Mouse; Immunopharmacology and Immunotoxicology, 22(3), pp. 433-449, 2000.	
	20	GABRIEL FERNANDES, ET AL., Increased TGF- β and Decreased Oncogene Expression by w-3 Fatty Acids in the Spleen Delays Onset of Autoimmune Disease in B/W Mice; J. Immunol. 152: pp. 5979-5987, 1994.	
	21	P. H. LAMBERT, ET AL., Pathogenesis of the Glomerulonephritis of NZB/W Mice; J. of Exp. Med. 127: pp. 507-527, 1968.	
	22	MICHAEL G. HAYEK, ET AL., Dietary Conjugated Linoleic Acid Influences the Immune Response of Young and Old C57BL/6NCrHBR Mice; J. Nutri. 129: pp. 32-38, 1999.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

5574591